Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F6JC
|
|||
| Former ID |
DCL000406
|
|||
| Drug Name |
Daprodustat
|
|||
| Synonyms |
GSK1278863; Daprodustat; 960539-70-2; GSK1278863; UNII-JVR38ZM64B; GSK-1278863; JVR38ZM64B; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; Daprodustat [USAN:INN]; GSK 1278863; Daprodustat(GSK1278863); Daprodustat; GSK1278863; Daprodustat (JAN/USAN/INN); GTPL8455; Daprodustat (GSK1278863); CHEMBL3544988; KS-00000M8Z; EX-A1121; BCP16766; s8171; AKOS027439964; Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-; ZINC231226004; CS-5453; SB19761; DB11682; HY-17608; J3.560.573H; D10874
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anaemia [ICD-11: 3A90; ICD-10: D64.8] | Approved | [1] | |
| Autism spectrum disorder [ICD-11: 6A02; ICD-10: F84.0; ICD-9: 299] | Phase 2 | [2], [3] | ||
| Diabetic foot ulcer [ICD-11: BD54; ICD-9: 707] | Phase 1 | [4] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C19H27N3O6
|
|||
| Canonical SMILES |
C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O
|
|||
| InChI |
1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)
|
|||
| InChIKey |
RUEYEZADQJCKGV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 960539-70-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HIF-prolyl hydroxylase 1 (HPH-1) | Target Info | Inhibitor | [5] |
| KEGG Pathway | HIF-1 signaling pathway | |||
| Pathways in cancer | ||||
| Renal cell carcinoma | ||||
| Panther Pathway | Hypoxia response via HIF activation | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | ||||
| Reactome | Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216951. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8455). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030089) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.